Journal issues > Issue SPECIAL, January 2021 > Which MAC or RIC for which AML patient?

Which MAC or RIC for which AML patient?

During the the 36^th general annual meeting of the Belgian Haematology Society prof. Frédéric Baron addressed an interesting question; which conditioning regimen should be chosen for which acute myeloid leukaemia (AML) patient? As you will find out in this report, the answer to this question is not so straight forward.

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top